Cocky Perhaps Confident Absolutely And thats

first_imgCocky? Perhaps. Confident? Absolutely. And that’s a good thing.Cornerbacks have it tough, as today’s rules are meant to make it more difficult to stop receivers. If Peterson can live up to his potential then he, along with Dominique Rodgers-Cromartie, Adrian Wilson and Kerry Rhodes can form one of the better secondaries in the NFL. He has the size, the tools and the swagger. However, only time will tell if stardom is really in his future. Cardinals expect improving Murphy to contribute right away D-backs president Derrick Hall: Franchise ‘still focused on Arizona’ Well, Peterson has his sights set on a bigger piece of real estate, as he told USA Today.“I don’t want an island,” the fifth overall selection in the second prime-time draft said. “I want a universe.” Expectations are high for Patrick Peterson, and there is hope his addition will give the Cardinals one of the better secondaries in the NFL.On his own, though, people are talking about Peterson in the same way they do New York Jets corner Darrelle Revis, who is so good that he is left to cover receivers without any help. The scenario has been dubbed “Revis Island”, as the only inhabitants are the corner and whatever wideout he is matched up against. Legend has it once you arrive you are rarely, if ever, heard from again. Nevada officials reach out to D-backs on potential relocation Comments   Share   What an MLB source said about the D-backs’ trade haul for Greinke Top Stories last_img read more

4 Birmingham to Dubai 3483 £360 10 pence

first_img4Birmingham to Dubai3,483£36010 pence RankingJourneyDistance (miles)CostCost per mile 5London to Sharm El Sheikh2,411£2078 pence 6London to Malaga1,042£303 pence 2New York to Singapore10,000£2,00021 pence RelatedTransatlantic flight deals and what to expect when you fly low-cost long-haulMore and more airlines have started running cheap transatlantic flights from the UK to the US, Canada and Mexico – but are those prices just too good to be true? Make sure you get the best all-round deal by finding the cheapest long-haul flights out there and reading our short…High Mileage – Low Cost? Round-the-world with (mostly) budget airlinesI wrote a piece about this last year in happier financial times, but since then various airlines have gone bustThe best time to book cheap flights to Australia? We have the answerEver wondered which city gives you the best value flight to Australia? Perth is the closest Australian gateway and often the cheapest route Down Under. Check out the best time to book flights to Perth.center_img 3Edinburgh to London400£3611 pence With Boeing announcing plans to develop the first non-stop flight from London to Sydney by 2020, we take a look at some of the world’s longest and shortest flights to reveal which routes offer the best value per mile.1. Westray (WRY) to Papa Westray (PPW) – £5.70 per mileThis two-minute island-hop in Scotland’s windswept Orkney Isles (pictured) lays claim to being the shortest commercial flight on the planet, as well as one of the world’s most beautiful air journeys. No need for in-flight entertainment on this route, which will cost you £17 one-way.2. Newark Liberty International Airport (EWR) to Singapore Changi (SIN) – 21 pence per mileConnecting Asia with North America, the world’s longest flight is Singapore Airlines’ 9,519-mile, 18.5-hour journey between New York Newark and Singapore, notoriously pricey with the cost of an average ticket around £2,000.3. Edinburgh (EDI) to London Gatwick (LGW) – 11 pence per mileOne of the UK’s most searched for routes, this 331-mile trip between the Scottish and English capitals takes only around an hour and costs around £36. 4. Birmingham (BHX) to Dubai (DXB) – 10 pence per mileThe United Arab Emirate state of Dubai (pictured) has emerged as one of the UK’s favourite long-haul holiday destinations in recent years, and it’s perhaps no surprise with one-way tickets for the seven-hour 3,483 journey coming in at only £360.5. London Gatwick (LGW) to Sharm El Sheikh (SSH) 8 pence per mileA popular route for Brits looking for year-round sun, the 2,411 mile journey from London to the tourist hotspot of Sharm El Sheikh comes in at £207 and equates to only 8 pence per mile.6. London Stansted (STN) to Malaga (AGP) – 3 pence per mileThe most searched for journey on Skyscanner in 2011, a one-way ticket to the sun-kissed Costa Del Sol can be yours for only £30, and the 1,042 mile journey comes in at a bargain three pence per mile, leaving you plenty to spend on ice cream and cold beers by the pool. To put this in perspective, the price of unleaded petrol at the time of writing was 140p per litre, equating to 18p per mile or nearly six times as expensive per mile as flights to Malaga. 1Westray to Papa Westray3£17£5.70 • All flight prices taken from Skyscanner and correct as at 30 March 2012 for the cheapest one-way fare available on 1 July 2012• Westray to Papa Westray can only be booked by telephone via Loganair• Petrol prices taken from and• Distances taken from mapcrow.infoReturnOne wayMulti-cityFromAdd nearby airports ToAdd nearby airportsDepart14/08/2019Return21/08/2019Cabin Class & Travellers1 adult, EconomyDirect flights onlySearch flights Maplast_img read more

New Alzheimers drug shows hints of promise in inventive trial

first_img Sign up for our daily newsletter Get more great content like this delivered right to you! Country A new antibody drug cleared protein plaques (right) that form around neurons in Alzheimer’s disease. Click to view the privacy policy. Required fields are indicated by an asterisk (*) Email National Institute on Aging/National Institutes of Health New Alzheimer’s drug shows hints of promise in inventive trialcenter_img Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe By Kelly ServickJul. 26, 2018 , 11:25 AM In the hunt for a drug to treat Alzheimer’s disease, even a whiff of success can be intoxicating. That helps explain why an experimental drug called BAN2401, which a few months ago seemed like it might join a growing heap of failed candidates, created so much buzz yesterday at the Alzheimer’s Association International Conference in Chicago, Illinois.In a phase II trial, the drug had already failed to show the level of benefit that its developers—Biogen Inc. in Cambridge, Massachusetts; and Eisai Co. Ltd. in Tokyo—set as the study’s primary endpoint. But yesterday the companies presented a series of other analyses from the same trial that suggest BAN2401 might slow the pace of cognitive decline in Alzheimer’s patients, and reverse the buildup of a brain protein thought to drive the disease’s neurodegeneration. But the subset of patients who showed those benefits was relatively small—161 people—and an unexpected change to the way the study was randomized cast some skepticism on the results. For many, the findings are too preliminary to celebrate.“If these results we saw today pan out in phase III clinical trials, then you’re looking at disease-modifying medication—the first one for Alzheimer’s disease,” says Keith Fargo, director of scientific programs & outreach at the Alzheimer’s Association in Chicago, Illinois. “But you don’t know whether they’re going to pan out until you actually do the phase III trial.” Like several other Alzheimer’s drugs under development, BAN2401 targets β-amyloid, the protein fragment that forms sticky plaques around neurons. Many scientists believe β-amyloid is a key culprit in Alzheimer’s disease, blocking communication between neurons and eventually killing them. BAN2401 is an antibody that binds to and helps clear out β-amyloid structures known as protofibrils that are in the process of clumping into plaques.The trial included 856 patients with a mild, early form of Alzheimer’s, and relied on a new measure of cognitive function—the Alzheimer’s Disease Composite Score (ADCOMS)—designed to detect subtle changes in people with early-stage disease. The companies also decided on an innovative and complicated study design. The trial would be “adaptive”; instead of randomly assigning an incoming participant to one of five treatment groups, each getting a different dose of the drug, the assignment system increased the likelihood that a patient would receive the dose that seemed to be working the best at the time they entered the study.The researchers also relied on a statistical method—known as Bayesian statistics—to analyze how the different groups of patients were responding to the drug while the trial was underway, rather than waiting until it was complete to do the statistical analysis. That approach was meant to give researchers an earlier hint about whether the drug was likely to work. This was the first use of Bayesian statistics in an Alzheimer’s trial, Fargo says. “I think the company felt very good about this drug,” he says, and thought Baysesian analysis could enable “a faster decision about whether or not to go to phase III.”But the strategy seems to have backfired. That early analysis, 12 months into the treatment, was supposed to reveal at least an 80% probability that BAN2401 reduced the rate of cognitive decline by 25% or more, compared with a placebo. The drug didn’t clear that bar, Biogen and Eisai revealed in December 2017. Instead, the probability was judged to be 64%, explained Lynn Kramer, chief clinical officer of Eisai’s neurology division, in yesterday’s presentation—“relatively close,” he said.But after following patients for another 6 months, the companies were much more optimistic. They announced earlier this month that in some patients, the drug had significant effects after all. And today’s presentation was the first glimpse at the size of those effects: After 18 months, the 161 patients getting the highest of five doses tested in the trial had 30% slower cognitive decline than those getting a placebo, as measured by the ADCOMS. That group saw a 47% slower decline than the placebo by another, more traditional cognitive measure, known as the Alzheimer’s Disease Assessment Scale-cognitive subscale. Brain imaging also revealed that the drug reduced levels of amyloid plaques in all the dosing groups, and that 81% of participants were judged to be “amyloid negative” in a brain scan after 18 months of treatment.But Kramer also described an unanticipated and potentially problematic change to the trial. The investigators monitored patients for swelling of the brain, a potential safety risk of this and other antiamyloid antibodies—particularly in patients with a gene called APOE4, which increases risk of Alzheimer’s and is linked to faster cognitive decline. In July 2014, a regulatory agency outside the United States—the companies didn’t specify which one—requested that the trial stop assigning these APOE4 carriers to the highest dose (and potentially highest risk) arm of the trial. The company complied with that request.That move not only reduced the size of the high-dose group, but it created a potentially confounding variable: Did that group show a slower mental decline because the drug was working, or because it contained fewer people genetically prone to decline quickly?In part because of that change, “I think probably people aren’t quite as excited as they were beforehand,” Lawrence Honig, a neurologist at Columbia University’s Vagelos College of Physicians and Surgeons, says about yesterday’s presentation. He was not involved in the study, but is an investigator on other studies of drugs developed by both Eisai and Biogen. The change to the study’s randomization “does affect the interpretation a little bit,” Honig says, although, “even without these caveats, [the trial] would not be conclusive.” He notes that other Alzheimer’s drug candidates have looked promising in phase II and failed in a larger study.It’s not yet clear what kind of study Biogen and Eisai will need to run next to prove the drug’s effectiveness to the U.S. Food and Drug Administration. Their follow-up will be one of a few closely watched efforts in this class of drug candidates. The companies are also jointly developing a different amyloid-targeting antibody, aducanumab, which catapulted straight into a large phase III study in 2015 after promising indications of benefit in just 125 patients. That study is expected to produce results in 2020.last_img read more